TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01594957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCQ908
Description: Participants will receive a single oral dose of LCQ908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCQ908
Description: Participants will receive a single oral dose of LCQ908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCQ908
Description: Participants will receive a single oral dose of LCQ908
Study: NCT00112359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZLI 75 mg three times a day (TID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo three times a day (TID)
Study: NCT03205072

Intervention type: DEVICE
Intervention: Spy Glass DS
Description: The SpyScope™ DS Access and Delivery Catheter (SpyScope™ DS Catheter) is a sterile, single-use endoscope that enables access and delivery of accessories to targeted pancreaticobiliary anatomy and displays live video when connected to a Spy Glass DS Digital Controller.
Study: NCT00508469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav)
Description: One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% eye drops
Description: One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol 0.05% eye drops
Description: One drop in the study eye twice daily at 9 a.m. and 9 p.m. for six months using the Travalert device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Travalert Dosing Aid
Description: Approved device used with study medication to record time of instillation and quantify dosing
Study: NCT01895582

Intervention type: OTHER
Intervention: Blood samples
Description: 4 blood tubes of lithium heparinate (5ml) 3 blood tubes of QTF-G-IT (1ml)~1 blood dry tube (5ml)

Intervention type: OTHER
Intervention: Blood samples
Description: 4 blood tubes of lithium heparinate (5ml) 3 blood tubes of QTF-G-IT (1ml)~1 blood dry tube (5ml)

Intervention type: OTHER
Intervention: Blood samples
Description: 4 blood tubes of lithium heparinate (5ml) 3 blood tubes of QTF-G-IT (1ml)~1 blood dry tube (5ml)
Study: NCT01362075

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia
Description: 150 ml ropivacaine, of which 100 ml is with adrenalin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene catheter
Description: 7 ml ropivacaine interscalene block via catheter, subsequently given 5 ml/h and possibility of 5 ml bolus for the first 48 hours.
Study: NCT04363866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine is more polar, less lipophilic, and has more difficulty diffusing across cell membranes than the parent compound, chloroquine. These characteristics result in hydroxychloroquine having a longer half-life, comparatively lower toxicity to chloroquine, as well as fewer concerns pertaining to drug-drug interactions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo is a pill that looks like the study drug but has no real medicine in it.
Study: NCT00508469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Travalert Dosing Aid
Description: Approved device used with study medication to record time of instillation and quantify dosing
Study: NCT00945269

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC
Study: NCT04655898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]CC-90001
Description: Oral
Study: NCT00757887

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Exposure to 5 P. falciparum infected mosquitoes
Description: Five Anopheles Stephensi mosquitoes are infected with NF54 P.falciparum. volunteers are exposed to bites for 10 minutes.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure to 5 P. falciparum infected mosquitoes
Description: Five Anopheles Stephensi mosquitoes are infected with NF54 P.falciparum. volunteers are exposed to bites for 10 minutes.
Study: NCT00945269

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: denileukin diftitox
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Optional correlative studies
Study: NCT01034254

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: influenza vaccine
Description: Pregnant women will receive FDA approved influenza vaccine.
Study: NCT03871712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interview
Description: The participants will be called twice with 2-4 weeks interval after the randomisation. This will be after 8 weeks of sick leave.
Study: NCT01034254

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: saline placebo
Description: Vaccination of pregnant women with saline placebo.
Study: NCT02909283

Intervention type: PROCEDURE
Intervention: Physical exams and blood analyzes
Description: Blood samples collection (for DNA, plasma and cells analyzes) ; Hemorheologic analyzes ; ASL sequence on MRI ; Near Infra Red Spectroscopy (NIRS) and associated cardiofrequency analyze.
Study: NCT00527553

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: not enriched egg
Description: daily consumption of a regular egg, not enriched with either lutien nor zeaxanthin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lutein
Description: daily lutein enriched egg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zeaxanthin
Description: daily zeaxanthin enriched egg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: egg product from enriched eggs
Description: daily egg product from lutein enriched eggs
Study: NCT00296231

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasal high frequency ventilation
Description: use of the high frequency ventilation mode of the Infant Star ventilator via a single nasopharyngeal prong.
Study: NCT03562559

Intervention type: OTHER
Intervention: Measurements Using Ultrasound
Description: Ultrasound measurements will be made in 5 positions. The ultrasound probe will be measuring from a fixed external location of the thigh. The 5 positions include: external rotation, neutral, manual tissue external rotation, straight leg raise at 30 degrees and hip/knee flexion at 90 degrees.
Study: NCT01615237

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audit and performance feedback (PF)
Description: Quarterly, trained clinic staff will use a standardized chart audit tool to evaluate documentation of cessation assistance. The feedback report will show individual and clinic performance summaries of two targeted provider behaviors based on documentation in the chart: 1) percentage of smokers advised to quit, and 2) percentage of smokers who received quitting assistance. Quitting assistance will be fulfilled by documentation of any of the following provider behaviors: a) Faxing a referral to the New York State (NYS) Quitline, b) Chart documentation of providing cessation counseling; and/or c) discussing and or prescribing cessation medications. Reports will be given to the Dental Director, who will be instructed to distribute them to dental providers no later than 30 days following the end of the quarter.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audit and performance feedback (PF)
Description: Quarterly, trained clinic staff will use a standardized chart audit tool to evaluate documentation of cessation assistance. The feedback report will show individual and clinic performance summaries of two targeted provider behaviors based on documentation in the chart: 1) percentage of smokers advised to quit, and 2) percentage of smokers who received quitting assistance. Quitting assistance will be fulfilled by documentation of any of the following provider behaviors: a) Faxing a referral to the New York State (NYS) Quitline, b) Chart documentation of providing cessation counseling; and/or c) discussing and or prescribing cessation medications. Reports will be given to the Dental Director, who will be instructed to distribute them to dental providers no later than 30 days following the end of the quarter.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial Incentive (P4P)
Description: We will review charts of all smokers to evaluate documentation of cessation assistance (i.e., prescription given for cessation medication, the provision of brief cessation counseling and/or a fax referral to the NYS Quitline or other local cessation support program). Sites will receive $20 for each patient with chart documentation of receiving tobacco cessation assistance. The P4P reimbursement will be offered quarterly with an annual cap of $5000 to each site as employees are salaried.
Study: NCT03871712

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stratified vocational advice
Description: The participants will be called after the randomisation. The amount of calls/meetings will be decided after each call, but with a maximum of 4 for the high risk group. This may include physical meetings.
Study: NCT03273595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Study: NCT00945269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study: NCT03273595

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Trastuzumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epirubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study: NCT02943278

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Sleep Retraining
Description: Participants in this group you will spend just over 1 day at our sleep lab, starting around their usual bedtime and ending the following day. Over a 20 hour period participants will complete a sleep retraining session, which involves an opportunity to fall asleep every 30 minutes; we will wake participants up after a few minutes if they fall asleep.
Study: NCT01615237

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Current Best Practices (CBP)
Description: CBPs that will be implemented is consistent with the PHS recommended guidelines and is as follows: The dental care team will assess smoking status, deliver advice to quit, assess readiness to quit, provide patient education materials, a prescription for cessation pharmacotherapy and referral to the NYS Quitline, and document findings and treatment plan on the chart system. In New York State, the Quitline provides free medication for uninsured. As brief provider interventions have been shown to be effective, the recommended tobacco treatment protocol will require approximately 5-10 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Current Best Practices (CBP)
Description: CBPs that will be implemented is consistent with the PHS recommended guidelines and is as follows: The dental care team will assess smoking status, deliver advice to quit, assess readiness to quit, provide patient education materials, a prescription for cessation pharmacotherapy and referral to the NYS Quitline, and document findings and treatment plan on the chart system. In New York State, the Quitline provides free medication for uninsured. As brief provider interventions have been shown to be effective, the recommended tobacco treatment protocol will require approximately 5-10 minutes.
Study: NCT02943278

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep Hygiene
Description: Participants in this group will complete one session with a clinician focused on psychoeducation regarding sleep positive practices.
Study: NCT01157260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kremezin
Description: AST-120 2g three times a day
Study: NCT00121745

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G Dose 1
Description: Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose I 3- 6 Days 1-7, 15-21 7.5 x 10e9 cfu 500 ml

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G Dose 2
Description: Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose II 3- 6 Days 1-7, 15-21 1.1 x 10e10 cfu 500 ml

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G Dose 3
Description: Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose~III 3- 6 5 days/wk x 4 wks 3.0 x 10e10 cfu 500 ml

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G Dose 4
Description: Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose~IV 3- 6 5 days/wk x 4 wks 8.0 x 10e10 cfu 500 ml
Study: NCT00945269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies
Study: NCT00546936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: 0.5mg ranibizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: verteporfin
Description: Photodynamic therapy with verteporfin every 3 months for 1 year
Study: NCT00846352

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Variation in the time for performing bronchoscopy
Description: The study will compare outcomes amongst patients assigned to receive early bronchoscopy (within 36 hours of enrollment)versus those in whom bronchoscopy is delayed (5 days after enrollment).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Variation in the time for performing bronchoscopy
Description: The study will compare outcomes amongst patients assigned to receive early bronchoscopy (within 36 hours of enrollment)versus those in whom bronchoscopy is delayed (5 days after enrollment).
Study: NCT01615237

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Current Best Practices (CBP)
Description: CBPs that will be implemented is consistent with the PHS recommended guidelines and is as follows: The dental care team will assess smoking status, deliver advice to quit, assess readiness to quit, provide patient education materials, a prescription for cessation pharmacotherapy and referral to the NYS Quitline, and document findings and treatment plan on the chart system. In New York State, the Quitline provides free medication for uninsured. As brief provider interventions have been shown to be effective, the recommended tobacco treatment protocol will require approximately 5-10 minutes.
Study: NCT02616055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tesevatinib
Study: NCT04380558

Intervention type: OTHER
Intervention: Pulmonary rehabilitation
Description: Patients will be asked to answer two questionnaires about urinary incontinence symptoms (see outcomes) to assess the prevalence and the type of these symptoms.~They will subsequently participate in their usual pulmonary rehabilitation program consisting in 90min sessions (including endurance training, muscle strengthening and self-management), 3x/week for 8weeks (centre 1) or 2x60min sessions (including the same components), 3x/week for 8weeks (centre 2).
Study: NCT01330459

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone/acetaminophen
Description: Administration of 2 tablets 5/325mg hydrocodone/acetaminophen 45-90 minutes prior to procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of 2 tablets methylcellulose (placebo) 45-90 minutes prior to procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 800 mg oral ibuprofen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: 800 mg oral ibuprofen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: 2 mg oral lorazepam

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lorazepam
Description: 2 mg oral lorazepam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 20 ml 1% buffered lidocaine, injected

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: 20 ml 1% buffered lidocaine, injected
Study: NCT01568060

Intervention type: OTHER
Intervention: Infanrix-IPV data collection
Description: Safety monitoring: recording of adverse events using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form.
Study: NCT03675230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tomotherapy HD
Description: Patients with Medulloblastoma receiving Tomotherapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3DCRT
Description: Patients with Medulloblastoma receiving Three-Dimensional Conformal Radiation Therapy
Study: NCT00128050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rFactor VIIa (Eptacog alfa, NovoNordisk)
Description: rFVIIa will be admistered as single bolus at the dosage of 100 mcg/Kg b.w.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rFVIIa
Description: Patients with spontaneous supratentorial ICH will be treated with rFVII after hematoma evacuation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodiun chloride 0.9%
Description: Bolus injection of sodium chloride 0.9% after surgical hematoma removal
Study: NCT04636164

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Model Dermatology (deep neural networks; Build 2020)
Description: Physicians in the DNN group take pictures of the skin lesion and use the algorithm by uploading pictures.
Study: NCT00752011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-106
Description: Starting dose 2.0 mg/m\^2 by vein over 24 hours, Day 1 of 3 Week Cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Starting dose AUC of 4, administered by vein over 60 minutes, Day 1 of 3 Week Cycle.
Study: NCT00853463

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Alert
Description: The responsible physician will be notified that: 1) his or her patient is at high risk for VTE and 2) VTE prophylaxis should be considered in the Discharge orders
Study: NCT03544710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preoperative bathing with antiseptic
Description: Preoperative bathing with antiseptic was done as follows; Given warm water and a tablet soap containing chloroxylenol antiseptic.~Asked to bathe under supervision for standardization. Given a clean theatre gown to put on. Taken through the routine pre-operative preparation procedures which involved; Putting an intravenous cannula; administering prophylactic antibiotics. Administering intravenous normal saline 1 liter. taking off a blood sample (3mls) for blood grouping and cross matching. Putting urethral catheter for drainage of urine, Getting an informed consent from the client for the procedure to be done. Informing the theatre team.
Study: NCT01902368

Intervention type: OTHER
Group type: OTHER
Intervention: gluten free diet
Study: NCT02743338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Restriction
Description: Behavioral component of CBT-i. Sleep restrictions includes curtailing bed time to match sleep time as registered during the first week of treatment, and expanding bed time contingent upon increased sleep efficiency, until optimal balance between sleep time and sleep efficiency is reached. The first five weeks, therapist support is provided via written messages. The next five weeks, patient works independently. At the end of tenth treatment week, therapist and patient make plan for future.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Restriction
Description: Behavioral component of CBT-i. Sleep restrictions includes curtailing bed time to match sleep time as registered during the first week of treatment, and expanding bed time contingent upon increased sleep efficiency, until optimal balance between sleep time and sleep efficiency is reached. The first five weeks, therapist support is provided via written messages. The next five weeks, patient works independently. At the end of tenth treatment week, therapist and patient make plan for future.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Compression
Description: Behavioral component of CBT-i. Sleep compression includes gradually compressing bed time over several weeks to approach sleep time as registered during the first week of treatment, and stopping compression when optimal balance between sleep time and sleep efficiency is reached. The first five weeks, therapist support is provided via written messages. The next five weeks, patient works independently. At the end of tenth treatment week, therapist and patient make plan for future.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Compression
Description: Behavioral component of CBT-i. Sleep compression includes gradually compressing bed time over several weeks to approach sleep time as registered during the first week of treatment, and stopping compression when optimal balance between sleep time and sleep efficiency is reached. The first five weeks, therapist support is provided via written messages. The next five weeks, patient works independently. At the end of tenth treatment week, therapist and patient make plan for future.
Study: NCT01866215

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: cycling at 100W during 60 min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: cycling at 100W during 60 min

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fructose
Description: isocaloric nutrition with fructose, cream and whey protein during the 24 hour following a glycogen/intramyocellular lipid depleting exercise
Study: NCT02743338

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Additional CBT-i components
Description: After 5+5 weeks of either Sleep Restriction or Sleep Compression, a randomized sample from each treatment Group is offered additional components of CBT-i, such as Stimulus Control, Cognitive Restructuring, Relaxation and Visualization for 10 weeks, without therapist support. Component allocation based on individual analysis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Additional CBT-i components
Description: After 5+5 weeks of either Sleep Restriction or Sleep Compression, a randomized sample from each treatment Group is offered additional components of CBT-i, such as Stimulus Control, Cognitive Restructuring, Relaxation and Visualization for 10 weeks, without therapist support. Component allocation based on individual analysis.